focus -WSS

focus

author：Wikipedia 2025-09-29 22:47:09 - browse：313

Illustration of a red human heart with an EKG line in the middle. -- health coverage from STAT — Adobe

Just weeks after Novo Nordisk announced that its obesity drug Wegovy cut the risk of heart complications in a major trial, the company now has results from a different study showing the treatment can also benefit people with a common type of heart failure.

The results, published Friday in the New England Journal of Medicine, found that among people with obesity and heart failure with preserved ejection fraction, or HFpEF, those taking Wegovy experienced greater improvements in symptoms and physical function compared with those on placebo. The improvements were greater than what’s been seen in trials of some other HFpEF treatments.

Novo previously shared topline results in investor calls, but the new study contains the full findings, which are also being presented at the European Society of Cardiology conference this week.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Donald Trump's relentless attacks on special counsel Jack Smith

WSS

The story of mRNA: From a loose idea to a tool that may help curb Covid

Insmed lung disease drug hits target in key Phase 3 trial

The strategy behind pharma's lawsuits over drug pricing reform

WATCH: Why do fingernails fall off when they're damaged?

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

The strategy behind pharma's lawsuits over drug pricing reform

hotspot

focus

Wikipedia

Activists slam private health insurers over coverage restrictions

Focused ultrasound for uterine fibroids: an uphill battle

Virginia high school admissions case could be legal follow

Death of patient in Alzheimer’s trial raises question of possible risks

Anesthesiologist group: stop taking Ozempic before surgery

Insmed lung disease drug hits target in key Phase 3 trial

Hollywood unions extend contract negotiations for actors

Startling documents reveal new facets of Sacklers' opioid empire

Sports medicine is finally prioritizing gender equality

Gene therapy has helped boys walk. Can scientists keep it that way?

focus

Death of patient in Alzheimer’s trial raises question of possible risks

Focused ultrasound for uterine fibroids: an uphill battle

Gene therapy has helped boys walk. Can scientists keep it that way?

Ask STAT: What do you want to know about ChatGPT in medicine?

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

Addiction doctors spar with methadone clinics over legislation

explore

hotspot

hotspot

hotspot